A phase 3 clinical trial published in Ophthalmology evaluated veligrotug in adults with moderate-to-severe active thyroid eye disease. A total of 113 patients received veligrotug (n=75) or placebo (n=38), randomized 2:1, with veligrotug administered at 10 mg/kg every 3 weeks for 5 intravenous infusions. Baseline characteristics were balanced between the two arms. Improvements were observed at week 3, with significantly greater responses at week 15 for veligrotug versus placebo across all primary and secondary endpoints (P<0.001).

Proptosis responder rates were 70% versus 5% by Hertel exophthalmometry and 71% versus 9% by magnetic resonance imaging or computed tomography. Overall responder rates were 67% versus 5%. Mean proptosis reduction was 2.90 versus 0.48 mm by Hertel and 2.96 versus 0.58 mm by magnetic resonance imaging or computed tomography. Diplopia improved in 59% versus 20%…